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1477-8939/ª 2014 Elsevier Ltd. All rigSummary Leishmaniasis is a vector-borne protozoan infection whose clinical spectrum
ranges from asymptomatic infection to fatal visceral leishmaniasis. Over the last decades,
an increase in imported leishmaniasis cases in developed, non-endemic countries, have been
pointed-out from a review of the international literature. Among the possible causes are
increasing international tourism, influx of immigrants from endemic regions and military oper-
ations. The main area for the acquisition of cutaneous leishmaniasis, especially for adventure
travelers on long-term trips in highly-endemic forested areas, is represented from South Amer-
ica, whereas popular Mediterranean destinations are emerging as the main areas to acquire
visceral variant. Leishmaniasis should be considered in the diagnostic assessment of patients
presenting with a compatible clinical syndrome and a history of travel to an endemic area,
even if this occurred several months or years before. Adventure travelers, researchers, mili-
tary personnel, and other groups of travelers likely to be exposed to sand flies in endemic
areas, should receive counseling regarding leishmaniasis and appropriate protective measures.
ª 2014 Elsevier Ltd. All rights reserved.1. Introduction
Leishmaniasis (or ‘leishmaniosis’) is a vector-borne obligate
intracellular protozoan infection (Kinetoplastida, Trypano-
somatidae) whose clinical spectrum, depends largely both
on parasite species and host immune response. The diseaseo Biomedico di Medicina Interna e
o@unipa.it (P. Mansueto).
14.09.007
hts reserved.ranges from asymptomatic infection to three main clinical
syndromes: visceral leishmaniasis (VL) also known as ‘kala-
azar’, cutaneous leishmaniasis (CL), and mucosal or
mucocutaneous leishmaniasis (ML) also known as ‘espun-
dia’. Although the disease has been known and studied for a
long time, it remains a public health problem worldwide,Specialistica, Via del Vespro n129, 90127, Palermo, Italy. Tel./fax:
564 P. Mansueto et al.affecting approximately 12 million people in 88 countries
(350 million inhabitants, mainly in remote rural areas and
underserved urban areas. Based on geographical distribu-
tion, leishmaniasis is divided into ‘Old World’ (southern
Europe, Mediterranean basin, Middle East, Asia, and Africa)
and ‘New World’ (Latin America) leishmaniasis. The means
of leishmaniasis transmission are hematophagous female
sand flies (order Diptera, family Psychodidae, subfamily
Phlebotominae) of the Phlebotomus genus in the Old
World, and of the Lutzomyia genus in the New World.
Nevertheless, fewer than 50 of the approximately 1000
species of sand flies worldwide are vectors of leishmaniasis.
This could be attributable to the inability of some sand fly
species to support the development of parasite infective
stages in their gut, and/or a lack of ecological contact with
reservoir hosts [1]. Other possible means of transmission of
lesser importance are blood transfusions, or in immune-
depressed intravenous-drug users, as a result of needle
sharing, or following organ transplantation, or via congen-
ital transmission, vertically or mother to child [2]. There
are more than 20 Leishmania species known to infect
humans. A female sand fly ingests Leishmania amastigotes
while blood-feeding, and then transmits the parasite in
infective stages (usually assumed to be the metacyclic
promastigotes) during a subsequent blood meal. The
infective promastigotes inoculated by the sand fly are
phagocytosed in the mammalian host by macrophages and
related cells, within those cell promastigotes transform
into amastigotes and often provoke a cutaneous ulcer at
the site of the bite [3].
In the last decade leishmaniasis expanded or emerged in
several foci worldwide due to climate and human factors
(e.g. deforestation, urbanization) [4], and some models
predict that sand flies will further expand with global
warming [5]. In addition, the widespread emergence of
Leishmania species resistant to pentavalent antimonials in
India, where half of VL cases occur globally, as well as the
HIV co-infection (in Northwest Ethiopia up to 30% of VL
cases are HIV-co-infected), leishmaniasis has become the
third most frequent opportunistic parasitic disease after
toxoplasmosis and cryptosporidiosis, which compromises
control of the disease [6e8].
1.1. Cutaneous leishmaniasis
Of all the forms of leishmaniasis, CL is the most common. A
review of international literature show that in the pub-
lished cases of imported travel-related leishmaniasis over
the past 25 years nearly 80% have concerned CL [9]. Ac-
cording to recent estimates, CL is endemic in 88 different
countries, 72 of which are developing nations, placing
nearly 350 million people at risk of infection and disease,
1.5 million new cases each year. More than 90% of cases
occur in five countries in the Old World (Algeria, Saudi
Arabia, Iran, Iraq, and Afghanistan) and two countries in
the New World (Brazil and Peru) [2]. CL is more common in
rural areas, in settings ranging from rainforests (jungle
environments) to arid regions; however it is increasingly
reported in urban and suburban areas of the Old and New
World, where a number of opportunistic hosts, such as dogsand donkeys, have become the reservoirs of infection,
reproducing a pattern similar to the VL caused by Leish-
mania infantum in the Mediterranean basin [10]. Main
species involved in CL are: Leishmania tropica, Leishmania
aethiopica, Leishmania major, and L. infantum in the Old
World, and parasites belonging to the Leishmania (Leish-
mania [L.] amazonensis, Leishmania [L.] mexicana, Leish-
mania [L.] venezuelensis), and Viannia (the Leishmania
braziliensis complex, with two species, L. [V.] braziliensis
and Leishmania [V.] peruviana, the Leishmania guyanensis
complex, with three species, L. [V.] guyanensis, Leishmania
[V.] shawi, and Leishmania [V.] panamensis), the Leish-
mania naiffi complex, with one species, L. [V.] naiffi, and
the Leishmania lainsoni complex, with one species, L. [V.]
lainsoni) subgenus in the New World (the so-called New
World or American CL, ACL). While most of the Old World
species cause benign cutaneous disease, New World species
cause a spectrum of disease, ranging from mild cutaneous
disease to severe mucosal lesions, depending to multiple
parameters, including immune status of the host and the
infecting species [2]. More in details, manifestations of ACL
include acute/localized cutaneous leishmaniasis (LCL),
anergic diffuse cutaneous leishmaniasis (DCL), also referred
to as disseminated cutaneous leishmaniasis in literature,
and mucocutaneous leishmaniasis (ML, see below). In the
middle of this broad clinical spectrum is LCL, the most
common form of ACL. Whenever Leishmania infection is not
controlled (i.e. inadequate treatment, poor compliance, or
development of an immunosuppressive state), it can prog-
ress to one of two polar forms, either exhibiting cellular
hyposensitivity, as in the cases of DCL, or cellular hyper-
sensitivity, as in ML. Additionally, an intermediate/
borderline disseminated cutaneous leishmaniasis (ICL or
BDCL) pattern has recently been identified as a distinct
nosological entity, representing an intermediate between
LCL and either of the extreme forms, DCL and ML, similar to
DCL for its chronic evolution, tendency to relapse, and
partial resistance to standard antileishmanial therapy. Cell-
mediated immunity, particularly T-cell-mediated one, plays
an important part in the immunologic response to Leish-
mania infection. A type 1 T helper (TH1) predominant
response is related to cure, while a TH2 predominant
response or the lack of an adequate TH1 response are both
associated with worsening of disease and/or treatment
failure. Individuals affected by ACL who manifest with LCL
are characterized as immune responders, whereas those
who manifest with disseminated disease (i.e., DCL) are
described as non-responders. Those who manifest with ICL
have an intermediate degree of responsiveness. Looking at
the immune response, if LCL develops a TH1 predominant
response, with production of TH1-related cytokines (mainly
IFN-g and TNF-a), DCL has a TH2 predominant one, with
production of TH2-related cytokines (mainly IL-4 and IL-10).
In contrast, as would be expected, in the ICL subset there is
a mixed cytokine profile, with at least partially preserved
TH1 immune response. Any member of the subgenera
Leishmania and Viannia represents the possible etiologic
agents of LCL. However, L. [V.] braziliensis is regarded as
the most important parasite associated with this form of
disease in the Americas. In cases of LCL caused by L. [V.]
Table 1 Cutaneous leishmaniasis patterns, main aetiological agents, and histopathological features.
Cutaneous leishmaniasis patterns Main aetiological agents Histopathological features
Old world cutaneous leishmaniasis L. tropica, L. aethiopica,
L. major, L. infantum
Epithelioid granuloma
New World (or American) cutaneous
leishmaniasis (ACL)
 Acute/localized cutaneous
leishmaniasis (LCL)
L. [V.] braziliensis
L. [L.] amazonensis
Epithelioid granuloma
Macrophagic granuloma
 Anergic diffuse cutaneous
leishmaniasis (DCL)
L. [L.] amazonensis
L. [L.] mexicana
Macrophagic granuloma
 Intermediate/borderline
disseminated cutaneous
leishmaniasis (ICL or BDCL)
L. [V.] braziliensis Nodular infiltration of lymphocytes
and plasma cells in the dermis, with
rare macrophages and parasites
 Mucosal or Mucocutaneous
leishmaniasis (ML)
L. [V.] braziliensis
L. [V.] guyanensis
L. [V.] panamensis
Tuberculoid granulomatous reaction,
with abundant infiltrate of lymphocytes
and plasma cells, with few histiocytes
and scanty parasites
L.: Leishmania; V.: Viannia.
Leishmaniasis in travelers 565braziliensis the histopathology of the lesions proves a
modest infiltration in the skin bordering the ulcerated
lesion, and scanty macrophages and parasites, whereas
lymphocytes and plasma cells are more frequent in the
infiltrate, which has the characteristics of an epithelioid
granuloma, similar to that of Old World CL. More rarely, if
LCL is due to L. [L.] amazonensis, pathologists can highlight
a large infiltration at the edge of lesion, and a dense infil-
trate of vacuolated macrophages in the dermis, which are
full of amastigotes and give the infiltrate the appearance of
a macrophagic granuloma. In cases of DCL, L. [L.] ama-
zonensis and L. [L.] mexicana are the main causative
agents. In the dermis, the histopathological feature is a
severe infiltration of macrophages containing abundant
amastigotes, whereas lymphocytes and plasma cells are
rare, giving also to DCL lesion the typical aspect of a
macrophagic granuloma. Finally, parasites of the subgenus
Viannia, especially L. [V.] braziliensis, have been identified
as the major etiologic agent of ICL. The histology of this
picture normally shows a nodular infiltration of lympho-
cytes and plasma cells in the dermis, with rare macro-
phages and parasites (Table 1) [11,12].
1.2. Mucosal (or mucocutaneous) leishmaniasis
Although ML develops in just a small number of patients
with New World CL, its course is chronic and may be life-
threatening. Mucocutaneous lesions are typically not seen
in L. Mexicana Leishmania complex infections, except
(rarely) in L. [L.] amazonensis infections. They are quite
frequent complications of the L. Viannia complex in-
fections and are seen more commonly in L. [V.] braziliensis
than in L. [V.] guyanensis or L. [V.] panamensis infections
[13]. In particular, as above-mentioned, three clinical
outcomes may derive from L. [V.] braziliensis infection,
probably due to the complex interactions with the host’s
imune system. In most cases a cellular immune reaction in
the inoculation site could lead to the elimination of the
parasites and to acquisition of immunity. Clinically, this
reaction results in LCL, characterized by skin nodules,ulcers, and sometimes regional lymphadenopathy. If
cellular immune response is inadequate, a cutaneous
dissemination of the parasite can occur (DCL): usually
these patients have lower levels of IFN-g and TNF-a pro-
duction than the ones suffering from localized forms,
thereby provoking less activation of the monocyte/macro-
phage immune reaction. In a subset of patients, the para-
sites spread via hematogenous or lymphatic routes and
invade the oropharyngeal mucosa, leading to ML. Here a
tubercoloid granulomatous reaction, with abundant infil-
trate of lymphocytes and plasma cells, with few histiocytes
and scanty parasites, causes thickening of the upper airway
walls, sometimes causing lumen obstruction, associated
with necrosis of the cartilaginous structures (Table 1). The
paucity of amastigotes in the granulomas, the strongly
positive Leishmania test result, and the high level of
circulating IFN-g and TNF-a suggest an exaggerated hy-
persensitivity reaction to the parasite, largely the result of
a prolonged antigen-specific TH1 activation [14,15]. As
additional pathogenic mechanism, Ronet et al. reported
that metastasizing, but not non-metastatic strains of L. [V.]
guyanensis, have high burden of non-segmented dsRNA
Leishmania viruses (Leishmania RNA Viruses, LRV). These
Leishmania viruses have been classified as Totiviridae,
which includes RNA viruses detected in other protozoa,
such as Trichomonas vaginalis and Giardia lamblia, and a
variety of fungi, including Saccharomyces cerevisiae. Toti-
viruses have a small unsegmented dsRNA genome, between
5 and 7 kb in length, which encodes a capsid protein and a
capsid-RNA dependent RNA polymerase (RDRP) fusion pro-
tein essential for their replication. Viral dsRNA is sensed by
the host Toll-like Receptor 3 (TLR3), thereby inducing, via
activation of the signaling TRIF (TIR-domain-containing
adapter-inducing interferon-b) cascade, a pro-
inflammatory response, with production of several cyto-
kines (IL-6, TNF-a), chemokines (CCL5 and CXCL10), and
NO, by iNOS activation via NFkB, then exacerbating and
diffusing the disease. In addition, the authors detected an
early upregulation of IFN-b, which is typically a sign of an
anti-viral immune response [16].
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VL is endemic in more than 60 countries in tropical and
subtropical areas, as well as in Mediterranean countries. It
has an annual global incidence of approximately 2 million
cases, and an increase of 500,000 cases yearly, 90% of which
concern six countries only e India, Nepal, Bangladesh,
Ethiopia, Sudan, and Brazil [17]. L. infantum in the Medi-
terranean basin, Leishmania donovani in the Indian sub-
continent, Asia, and eastern Africa, and Leishmania chagasi
(L. infantum MON 1) in South America are the main causes
of VL. Nowadays the most widespread is L. infantum, found
from the People’s Republic of China to the New World [18].
In Mediterranean countries and in South America, the dis-
ease is zoonotic and affects mainly infants and young
children [19]. However, in the Mediterranean basin, an
increasing rate of immune-compromised and immune-
suppressed adult individuals has been noted [7,20,21],
such as HIV co-infected patients and those under any
immunosuppressive therapies. In these countries stray and
domestic dogs and abundant sand flies are the main
reservoir for infection, and the VL cycle is sustained in well-
defined foci by a high prevalence (up to 25%) of canine
leishmaniasis. Consequently, in these areas there is a large
market for prophylactic drugs and treatment of canine
leishmaniasis [22,23]. In the Indian subcontinent and Af-
rica, VL is anthroponotic (human-to-human transmission
through sand flies, without the involvement of a reservoir
host) and affects both adults and children [2].
Over the last decade there has been an increase in im-
ported cases in developed, industrialized, non-endemic
countries, in association with increasing international
tourism, military operations, influx of immigrants from
endemic countries, and HIV-infected subjects [18,24e32].
This article reviews travel-acquired leishmaniasis with a
focus on epidemiology, clinical presentation, diagnosis, and
treatment. We researched the PubMed database for the
period from 1980 through December 31, 2013, using the
words ‘leishmaniasis’, ‘imported’, ‘travelers’, and ‘travel-
acquired’. Articles presenting original data on imported
leishmaniasis cases were included in our review, and review
articles were also studied. We found and examined 44 ar-
ticles presenting original data on travel-acquired leish-
maniasis [18,24,26e65].2. Leishmaniasis in international travelers
The popularity of international travel is increasing so
rapidly that approximately 1 billion international move-
ments occurred by the end of 2010, and 1.6 billion will
occur by 2020, most of which will take place in tropical and
subtropical areas. Such intense international traffic results
in greater vulnerability to the transmission of old, new and
re-emerging infectious diseases, with travelers playing a
leading role in disease dissemination [66e68]. More than
half of international travel is for leisure or for military
reasons, but an increasing number of travelers are immi-
grants visiting friends and relatives in tropical and sub-
tropical areas. International travelers are increasingly
involved in adventure travel and outdoor activities, whichrender them at increased risk of contracting leishmaniasis
[18,41,69]. CL and ML are emerging among travelers
involved in outdoor activities in endemic areas, and are
part of the top 10 diseases causing dermatological abnor-
malities among tourists returning from tropical countries
[25]. Furthermore, a significant number of VL cases have
been reported among travelers in recent years
[18,28,29,37]. In non-endemic countries the management
of leishmaniasis remains a challenge for physicians, and
delayed diagnosis and inappropriate treatment are
frequently encountered [24,26,28,29].
2.1. Cutaneous leishmaniasis
The main clinical expression of imported leishmaniasis,
involving more than 80% of cases in returning travelers, is
cutaneous, and LCL is, for sure, the most common expres-
sion pattern. Cases in travelers and military personnel are
almost invariably acquired in jungle environments [70].
However, limited information is available about the inci-
dence of CL in travelers for several reasons: (1) the number
of exposed people (i.e. the total number of travelers to
endemic areas) is often unknown; (2) the disease is
frequently misdiagnosed, given the lack of familiarity of
physicians in non-endemic countries; (3) it is not a report-
able disease in most industrialized countries (notification is
compulsory in only 32 of the 88 countries where 350 million
people are at risk); (4) spontaneous self-healing is possible.
Anyhow further reports from European countries show the
importance of CL among returning travelers with skin dis-
orders. In the UK an increase in the annual number of im-
ported L. [V.] braziliensis CL cases has been noted: from 4
to 18 per year between 1995 and 2003. As a possible cause
of this increase, the number of UK travelers to South
America, especially to highly endemic foci in Bolivia and
Belize, has increased 3e5 fold [26]. In a more recent paper,
Scarisbrick et al. examined, all patients with a clinical
diagnosis of CL seen at the Hospital for Tropical Diseases of
London, from 1997 to 2000. Forty-two patients were iden-
tified, 23 had traveled to New World countries and 19 to Old
World countries. Clinical presentation typically consisted of
a single nodule with ulceration. In 50% of cases infection
was caused by L. [V.] braziliensis [45]. Similar epidemio-
logical evidence showed that in the Netherlands the num-
ber of CL cases doubled between 1990 and 2000, with
Europe, Africa, Asia, and the New World (Latin America) as
the most common sources of infection [71]. More recent
data showed an increase in Netherlands patients diagnosed
with CL between 2005 and 2012 compared to the periods
from 1979 to 1988 and 1990 to 2000 [61]. CL in Guyana (an
overseas region of France) is the major source of exotic
cases imported to mainland France [41]. Ehehalt et al.,
within the European travel medicine network (Euro-
TravNet), performed a retrospective analysis in travelers
who acquired leishmaniasis within Europe and were diag-
nosed between 2000 and 2012. Thirty cases of CL (and 10 of
VL) were identified; the majority was acquired in Spain,
Malta and Italy, the most frequent reason for travel was
tourism [72].
In the USA most civilian CL cases are acquired in Central
America and Mexico; the estimated incidence is of one CL
Figure 1 Ulcerated dry lesion caused by Leishmania
Leishmaniasis in travelers 567case treated with antimonials per 1000 travelers to Suri-
name and one per 1 million travelers to Mexico [30]. Data
from the Geosentinel database for the period 1996e2004
show that CL is among the 10 most frequent dermatologic
disorders encountered in travelers, identifying South
America as the main area of infection, followed by Central
America [73]. It is noteworthy that few cases are acquired
in countries where the vast majority of the global burden of
leishmaniasis occurs e Indian subcontinent, Middle East,
and East Africa. This highlights the different epidemiologic
profile between imported and indigenous cases, probably
due to different exposure. Imported CL is most frequently
diagnosed among tourists and travelers for professional
reasons (military personnel, construction workers, re-
searchers), as well as immigrants and expatriates. Eco-
tourists, adventure travelers, soldiers, journalists,
photographers, and researchers on long-term trips who
work in forests during the night-time (e.g. geologists, vet-
erinarians) are at high risk for acquiring CL. In a 5.3-year
study of CL in US travelers, 39% occurred among tourists
and 46% among scientists traveling in Central and South
America. This represented one thousandth of the estimated
annual cases of CL in the USA (n Z 59,300) [30]. Even
though long-term travels in endemic areas represent a risk
factor for leishmaniasis infection, short-term travelers
should not be considered immune from risk. Males account
for 64e71% of all travel-acquired CL cases; this could be
attributable to the overrepresentation of men in high-risk
outdoor occupational activities [30,37,41,43]. Finally, CL
has also been reported in patients with no history of travel
to an endemic area, due to contact with sand flies imported
accidentally through various means of transport, from the
regions of residence of the cases [54,74]. For this reason
the International Health Regulations recommend disinfec-
tion of aircraft preflight, and blocks-away spraying with
pyrethroids [75].
2.2. Mucosal leishmaniasis
ML is rarely reported among western travelers returning
from endemic areas, nevertheless ML is increasingly iden-
tified nowadays in travelers from South America, with the
vast majority of cases acquired in rural or forest areas of
the Amazon basin in Bolivia, where highly endemic foci for
L. [V.] braziliensis exist. However, as indicated by our
research, there are no published data on the risk of trav-
elers with L. [V.] braziliensis CL progressing to ML
[26,32,76e78].
2.3. Visceral leishmaniasis
VL is rare in travelers [73]. Imported VL cases usually
concern adult male tourists, HIV-infected persons, or chil-
dren. Western European travelers mostly acquire VL in the
Mediterranean region, occasionally in Latin America, and
rarely in the Indian continent or East Africa
[18,28,29,37,43]. Imported VL cases to the UK during
1985e2004 were contracted in the countries of southern
Europe (i.e. Spain, Italy, Malta, Greece, and Cyprus), and
tourists accounted for 55.5% of them, while the remaining
patients were immigrants; since 2000, however, no newcases of VL have been reported in immigrants, and all new
patients were travelers returning from this geographical
region [29]. As already reported for the UK, most cases of
VL in the Netherlands were acquired in the south of Europe
[79,80]. Similarly, data from the German Surveillance Sys-
tem for Imported Diseases collected during 2001e2004
indicate that the vast majority (81%) of VL cases were ac-
quired in the countries of southern Europe, while almost
half (48%) of CL cases were acquired in South America.
Germans on holiday accounted for most imported cases in
Germany. However a significant number (19%) were non-
European immigrants. In this study the relative risk for
acquisition of leishmaniasis by geographic area was esti-
mated at 22.7% for South America, 5.4% for Asia, and 2.1%
for Africa, compared to southern Europe [43].
3. Clinical manifestations
3.1. Cutaneous leishmaniasis
Given the broad spectrum of the disease, the published
data on travelers with CL are insufficient and too hetero-
geneous to allow a comparison between travelers’ clinical
framework and patients from endemic areas. CL may
manifest with one or multiple skin lesions on the areas of
the body exposed to sand fly bites (single or multiple). The
onset of lesions may be within a few days or several weeks
after the sand fly bite. Occasionally the lesions may appear
months or years later [27,30,32]. As mentioned above, ACL
has variable clinical manifestations, ranging from a single
ulcerative skin lesion (LCL), the most frequent, to
destructive mucosal inflammation (ML), and is often
accompanied by local lymphadenopathy [81], whereas Old
World CL more often presents with multiple lesions [82].
Recent reports, however, indicate that some Leishmania
spp. endemics in the Old World (Southern Europe, Africa,
the Middle East and Asia) might entail mucosal involvement
[83e85], with face, upper limbs, and lower limbs as the
most frequently involved sites [18,30,45]. The initial CL
lesion is usually a gradually enlarging, erythematous, often
pruritic papule, which subsequently progresses to nodule
and then to ulcer during the next 1e3 monthsinfantum.
Table 2 New World (or American) Cutaneous Leishmaniasis (ACL) clinical manifestations.
New World (or American
cutaneous leishmaniasis
(ACL) patterns
First clinical manifestation Evolution Number of lesions
Acute/localized
cutaneous
leishmaniasis (LCL)
Gradually enlarging, erythematous
and often pruritic papule at site of
sandfly bite
Progression to nodule and then
to painless ulcer during the
next 1e3 months
One or few at site of
sandfly bite
Anergic diffuse
cutaneous
leishmaniasis (DCL)
Diffuse infiltration of the skin, on
which appear nodules, papules,
tubercules, and infiltrated plaques,
often disfiguring
Rare ulceration.
Rapid spreading of initial
lesions
Large number, especially
in the extremities
Intermediate/borderline
disseminated
cutaneous
leishmaniasis (ICL or
BDCL)
Verrucous, zosteriform, chancriform,
mycetoma-like, erysipeloid, lupoid,
psoriasiform, eczematoid, sarcoidal,
keloidal, paronychial, and
palmoplantar lesions
Secondary infection, resulting
in a purulent appearance, with
crust formation, and spreading
of the lesions 2e3 months
following initial infection
Hundred or more,
disseminated to the
whole body
Mucosal or
Mucocutaneous
leishmaniasis (ML)
Erythema and edema of nasal and
mouth mucosa, followed by
ulcerations covered with a
mucopurulent exudate
Ulcerative destruction of nose,
mouth, pharynx, and larynx
(hoarseness and dysphonia),
nasal septum perforation, and
facial disfigurement
Multiple lesions
spreading through the
airways mucosa
568 P. Mansueto et al.[24,32,36,38,39,41,50,62] (Fig. 1). Leishmanial ulcers are
typically painless and grow slowly with a granulomatous or
crusted base and raised inflammatory margins [86]. Painful
lesions are rare, but their appearance could be a predictive
sign of bacterial super-infection. Uncommon manifesta-
tions, especially in ICL, include verrucous, zosteriform,
chancriform, mycetoma-like, erysipeloid, lupoid, psoriasi-
form, eczematoid, sarcoidal, keloidal, paronychial, and
palmoplantar forms, not infrequently becoming secondarily
infected, resulting in a purulent appearance, with crust
formation, spreading, 2e3 months following initial infec-
tion, with the appearance of a hundred or more lesions.
DCL, the more rare, anergic form of ACL, is clinically
characterized by a diffuse infiltration of the skin, on which
appear a large number of nodules, papules, tubercules, and
infiltrated plaques, that rarely become ulcerated, and
often are disfiguring, resembling lepromatous leprosy. In
older cases of the disease, disseminated lesions, more
rapidly than in ICL, cover much of the body, but are pre-
dominantly on the extremities [2]. Skin lesions, sometimes
of several different types occurring simultaneously, may
persist for months or years [87e89]. Lymphatic spread, with
nodular lymphangitis (sporotrichoid distribution) and
regional lymphadenopathy are commonly seen in travelers,
especially the ones infected by L. [V.] braziliensis [38,41].
In infections caused by this parasite, lymphadenopathy may
even precede the appearance of cutaneous lesions, sug-
gesting early lymphatic spread of parasites [90]. Regional
lymphadenopathy has been observed in two-thirds of Bra-
zilian patients infected with L. [V.] braziliensis. In these
patients, 62% of lymph node aspirate cultures yielded
Leishmania parasites [91]. CL natural history varies
depending on the species, the location of the lesion, and
the immune status of the host. L. [L.] mexicana infections
usually cause one or a few lesions that heal spontaneously
within 6 months. In Mexicans infected by L. [L.] mexicana,
lesions on the ear, called Chiclero ulcers, occur in 40% ofpatients [92]. Non-immune visitors may have a different
evolution of the skin lesions and a lower responsiveness to
treatment compared to adults of the local population. A
study of histopathological parameters in people living in
endemic areas with a history of prior CL, as evidenced by a
typical scar, showed a higher frequency of giant and
epithelioid cells -the hallmarks of the granulomatous
response. They also had a lower number of parasites in
their lesions. These findings were correlated with a lower
dose of antimonials needed to achieve cure, indicating an
acquired immunity in the local population with better
response to treatment [93]. Despite the non-lethality of the
disease and the frequent spontaneous self-healing of le-
sions (especially due to Old World species) over months to
years, CL is often associated with significant morbidity and
may affect daily activities and social life when located on
the hands and face. In addition, even when cure is ach-
ieved, a psychosocial disability could persist due to dis-
figuration as a result of residual scarring and de-
pigmentation [27] (Table 2).
3.2. Mucosal leishmaniasis
ML probably results from early hematogenous (especially in
LCL cases) or lymphatic (especially in ICL cases) spread
from cutaneous lesions to the mucosal surfaces of the nose
or mouth (including tongue); this involvement might not be
noticed until years (up to 35 years) after healing of the
initial CL skin lesion. Generally, ML occurs in 1e10% of CL
cases, 1e5 years after healing. However, in endemic re-
gions, it is estimated that 1e10% of patients with mucosal
disease report no known previous cutaneous involvement.
Therefore, it is thought that a significant percentage of
infections remain subclinical, so patients may be unaware
of previous infection. Furthermore, given the potential for
a prolonged interval between resolution of cutaneous dis-
ease and development of mucosal lesions, the remote
Figure 2 Giemsa-stained skin scraping of a case with cuta-
neous leishmaniasis at 1000magnification showing histiocytes
loaded with amastigotes. Arrows indicate the nucleus and
kinetoplast, which are required to confirm that the inclusion is
indeed an amastigotes.
Figure 3 Skin biopsy specimen showing diffuse lymphohis-
tiocytic dermal infiltrate with numerous poorly formed non-
necrotizing epithelioid granulomas (hematoxylin-eosin,
original magnification 100) (A). Inset, histiocytes in the
papillary dermis with Leishmania parasites in the cytoplasm
(original magnification 1000) (B). In sections stained with
hematoxylin-eosin the parasites appear as haloed small dots
and the differentiation between the nucleus and the kineto-
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factors for progression to ML include male sex, large
(>4 cm2) or multiple lesions, location of the lesion on the
head or neck, long-standing skin lesions, for which
adequate systemic treatment has not been administered,
immune-suppression, malnutrition, and place of infection,
for example, in the high Andean countries, notably Bolivia.
In addition, it has long been suspected, but never definitely
proved, that the risk of developing ML has a genetic
component. Recently, an association between ML and HLA
has been demonstrated, with significant decrease in the
frequency of HLA-DR2 and a significant increase in HLA-
DQw3 among patients compared to controls [94e97].
Alcais et al. have proved that the risk of ML ranges from
three to ten times higher in migrants than in the indigenous
population, indicating that tourists may also be at higher
risk of developing ML than the local population [98]. Ery-
thema and edema of the mucosa are the typical onset, and
are usually followed by ulcerations covered with a muco-
purulent exudate. In contrast to CL, ML is not a self-healing
disease and may progress and cause permanent complica-
tions, such as ulcerative destruction of the nose, mouth,
pharynx, and larynx, nasal septum perforation, and facial
disfigurement resulting in social stigma. Without treatment
the outcome may be fatal because of the aforementioned
compromise of the airway. Patients with ML may complain
of stuffiness, difficulty in breathing through their nose, and
occasional bleeding as their first symptoms. Hoarseness and
dysphonia may indicate laryngeal involvement including the
vocal cords [26,32,38] (Table 2).
3.3. Visceral leishmaniasis
Viscerotropic Leishmania species infection usually results in
asymptomatic or mild illness followed by spontaneous res-
olution. Only one out of 30e100 infected cases develop
typical VL. Factors that predispose the development of
typical VL include youth, malnutrition, poverty, immune
deficiency, and high leishmanial load [99]. Progression time
to VL is usually about 2e8 months from contact with the
infectious agent, but longer periods are also reported;
significantly shorter cases, up to two weeks after infection,
have also been described in the literature [100]. Fever,
weakness, anorexia, weight loss, pallor, hep-
atosplenomegaly (usually splenomegaly predominates),
lymphadenopathy, and progressive deterioration of psy-
chophysical state, may be present from the early onset of
disease [19,101]. Late findings include epistaxis, gingival
hemorrhage, abdominal distension, ascites, and peripheral
edema [2]. Occasionally VL may manifest as acute hepati-
tis, cholecystitis, hemophagocytic syndrome, and Guillain-
Barre´ syndrome [19,102]. Growth retardation may be
noticed in children [103]. The natural history of VL includes
a mortality rate between 75 and 95%, with delayed diag-
nosis increasing disease complications, particularly in pa-
tients suffering from immune-suppressive diseases. Usually
exitus is caused by severe anemia, secondary infection, and
hemorrhage [104e108]. Laboratory findings include nor-
mocytic normochromic anemia, neutropenia, thrombocy-
topenia, hypoalbuminemia, hypergammaglobulinemia, and
increased transaminases [103]. HIV-infected patientsusually have higher parasite loads and atypical symptoms
(e.g. gastrointestinal), especially the ones with lower CD4
cell counts. In these cases VL is usually the result of relapse
after years of latency or is a newly-acquired infection. This
group of HIV-infected patients responds poorly to treat-
ment and rates of relapse are high, regardless of treatment
used [107,108]. American military personnel who served in
the Middle East in the early 1990s developed a viscerotropic
syndrome, characterized by prolonged fever, fatigue,
cough, abdominal pain, and diarrhea following infectionplast cannot be made.
Table 3 Cutaneous and mucosal leishmaniasis diagnostic methods.
Diagnostic test Expected result Notes
Microscopic examination of
Giemsa-stained skin
specimens by direct light
microscopy under oil
immersion
Visualization of the amastigote
parasite
Simple. Gives rapid results
(within 20 min).
Low sensitivity (about 14e18%)
Histological sections of skin
lesions, stained with
hematoxylin and eosin,
examined under light
microscopy
Detection of granulomas and
amastigotes
Granulomas are characteristic
of leishmaniasis, but not
diagnostic (tuberculosis,
sarcoidosis and fungal
infections, must be excluded).
Low sensitivity (33e57%)
Culture in special medium (i.e.
modified NovyeNicolle
eMcNeil medium, or NNN
culture, at 24e25 C for up
to 3 weeks) of yield fluid
from needle aspiration of
the lesion’s margins
Isolation of the organism and
identification of the species
Low sensitivity (58e62%)
Leishmanin skin test
(Montenegro test)
Assessment of delayed
hypersensitivity reaction to
Leishmania antigens
Positive in almost all patients
with active CL and ML.
It may be negative during the
first few months.
Positive for life.
Not routinely available in most
industrialized countries
Standard serological tests (i.e.,
gel diffusion, indirect
hemagglutination assay,
direct agglutination test,
complement fixation,
counter-current immune-
electrophoresis, Western
Blot, enzyme-linked
immunosorbent assay,
indirect
immunofluorescence test,
immunochromatographic
test)
Identification of anti-
Leishmania antibodies
Not useful for CL diagnosis.
Usually positive in ML.
Helpful in monitoring the
response of ML to treatment.
No species-specific diagnosis
Isoenzyme strains (zymodemes)
or monoclonal antibody
analysis on cultured
Leishmania
Species-specific diagnosis of
Leishmania infection
Not used as routine tests in
most laboratories
Leishmania polymerase chain
reaction (PCR) on skin lesion
samples (punch biopsy or
filter paper impressions)
Identification of parasite
genoma and species-specific
diagnosis
Low parasite load needed.
High sensitivity (98e100%)
High specificity (100%)
CL: cutaneous leishmaniasis; ML: mucosal leishmaniasis.
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cases) [109].
4. Diagnosis
The diagnosis of CL or ML in travelers is frequently delayed
from several months to years after symptom onset; similar
delays have been reported for VL cases in non-endemic
countries [26,29,37,38,41,43,45].4.1. Cutaneous and mucosal leishmaniasis
Physicians should consider CL and ML in a differential
diagnosis work-up of subjects with chronic, non-healing
skin and/or mucosal lesions who have a travel history in
endemic areas. Laboratory confirmation of CL is achieved
by detecting Leishmania parasites through microscopic
examination of Giemsa-stained skin specimens (Fig. 2).
Direct light microscopy under oil immersion, which allows
Leishmaniasis in travelers 571the visualization of the amastigote parasite by using slit
skin smear, obtained from the actively inflamed border of
the lesion or dabs, is very useful, simple, and gives rapid
results (within 20 min), and should be the first diagnostic
approach, although its sensitivity is about 14e18%
[110e112]. Punch biopsies with tissue-impression smears
could be an equally useful diagnostic tool. Histological
sections, stained with hematoxylin and eosin, are exam-
ined under light microscopy by a histopathologist to
search for granulomas and amastigotes (Fig. 3). Granu-
lomas are characteristic of leishmaniasis, but not diag-
nostic. Other granulomatous disease, such as tuberculosis,
sarcoidosis and fungal infections, must be excluded.
Needle aspiration from the margin of a lesion can yield
fluid for culture in special medium (i.e. modified
NovyeNicolleeMcNeil medium, or NNN culture, at
24e25 C for up to 3 weeks) to isolate the organism and
identify the species. However, all these methods suffer
from low sensitivity (58e62%), and pathologists may miss
the diagnosis or suggest the presence of infection from
Leishmania spp., particularly when parasites are not
visualized in the histopathological specimens. Considering
both the difficulties in identification of muco-cutaneous
lesions by physicians and poor sensitivity of diagnostic
tools, the Leishmania polymerase chain reaction (PCR)
analysis should be considered as a routine test in granu-
lomatous skin disease work-up, even when a diagnosis of
CL was not considered by the referring physician
[113,114]. The leishmanin skin test (Montenegro test),
related to delayed hypersensitivity reaction to Leishmania
antigens, is positive in almost all patients with active CL
and ML, although it may be negative during the first few
months. The test is thereafter positive for life. However,
it is not routinely available in most industrialized coun-
tries [26,43,71]. Standard serological tests (i.e. gel
diffusion, indirect hemagglutination assay, direct agglu-
tination test, complement fixation, counter-current im-
mune-electrophoresis, Western Blot, enzyme-linked
immunosorbent assay [ELISA], using promastigote antigen,
[ELISAp], or recombinant K39 [ELISA rK39], or K26 [ELISA
rK26] antigens, indirect immunofluorescence test, and
immunochromatographic test, using rK39 antigen) are not
useful for the diagnosis of CL, since they are often nega-
tive [115]. In contrast they usually become positive in ML.
Hence serology may be helpful in monitoring the response
of ML to treatment. The diagnostic methods discussed
thus far are genus-specific but not species-specific.
Determination of the species is clinically very important,
because different species require different clinical and
therapeutic approaches; in particular, species detection is
of importance since there is an overlap between Leish-
mania and Viannia species complexes in Central and South
America, and patients might have traveled through
several endemic areas confounding the possible detection
of species parasite through a geographical localization
based approach. For example, L. Viannia species may
cause a mucosal involvement and a systemic treatment is
recommended, whereas this is not required for most cases
of other CL. Unnecessary systemic therapy may be harm-
ful, since it can be associated with toxic adverse effects[116]. Until recently the two existing methods for species-
specific diagnosis of Leishmania infection were isoenzyme
strains (or zymodemes) or monoclonal antibody analysis
on cultured Leishmania, which are not used as routine
tests in most laboratories [117]. PCR and subsequent
sequencing of DNA products can permit the species iden-
tification of samples for which parasite culture remained
negative or did not allow isoenzymatic characterization
[118]. The multilocus sequence typing (MLST) and the
Matrix-assisted laser desorption ionization time-of-flight
(MALDI-TOF) mass spectrometry are promising ap-
proaches, providing rapid and accurate identification of
Leishmania from in vitro culture at the species level
[119,120].
PCR, especially using kinetoplast minicircle DNA or in-
ternal transcribed spacer of the multi-copy nuclear ribo-
somal genes, appears to be the best method for confirming
a diagnosis of CL, because of the low parasite load needed,
with a sensitivity of 98e100% and a specificity of 100%
[118,121,122]. PCR has also proved superior to conventional
methods in the diagnosis of ML, showing better sensitivity
(97e100%) than the direct visualization of parasites in bi-
opsies (hematoxylin-eosin staining) (33e57%), immunohis-
tochemical testing of biopsy sections (69%), culture (67%),
or serological testing (83%). However, leishmanial DNA may
persist in the skin of patients after complete healing,
resulting in possible confusion with other, unconnected
mucosal diseases. In the latter case, despite high positive
and negative predictive values, PCR results like those of
any laboratory test should be interpreted in the light of the
overall clinicopathological findings [26,123]. Two quick, in-
office techniques for PCR sampling currently available to
the clinician are punch biopsy and filter paper impressions.
The first involves 1e2 mm biopsies of the indurate active
margins of the ulcer, with part of the sample being used to
make tissue impression smears and the other being
exploited for PCR analysis. The second technique, which is
a simpler and much less invasive procedure, entails the
blotting of the lesion onto a special Whitman filter paper
that is subsequently analyzed. This method has the addi-
tional advantage of allowing easy specimen transport,
making it particularly appropriate to be used in areas
without access to high quality laboratory equipment
[124e127]. In the differential diagnosis of CL and ML, un-
specific skin reactions to insect bites, bacterial skin in-
fections (including staphylococcal infections, especially
MRSA, and streptococcal pyodermas, yaws, syphilis, cuta-
neous tuberculosis, Mycobacterium marinum infections,
leprosy, actinomycosis, and rhinoscleroma), mycosis
(including, blastomycosis, coccidioidomycosis, para-
coccidioidomycosis, histoplasmosis and sporotrichosis),
cutaneous larva migrans, granulomatous disease (Wegener
granulomatosis and sarcoidosis) and tumors (lymphoproli-
ferative disease, extranodal NK-T-cell lymphoma, or
midline granuloma, and nonkeratinizing squamous cell
carcinomas) are the most frequent misdiagnoses. When the
lesions are (1) small in number (2) located on exposed body
surfaces, (3) not painful, (4) persist for several months, and
(5) resist all types of administered treatment, CL should
quickly ascend to the top of the differential. This profile is
Table 4 Cutaneous and mucosal leishmaniasis treatment.
Leishmaniasis patterns Treatment
Old World CL
 Single, stable lesion under
10 mm diameter on non-exposed
areas in an immunocompetent patient
 More than one lesion in exposed area
 Three or more lesions larger
than 4e5 cm, located in sensitive areas
 Intervention is not always necessary, as the ulcers should
spontaneously regress within 2e4 months
 Topical treatment with intralesional injections (see New World CL)
 Systemic therapy (see ML)
New World CL
 Skin lesion (<4 cm), exclusively
when no risk for ML seems plausible
 Local treatment:
 Local infiltration of pentavalent antimony (every 5e7 days,
for a total of 2e5 times)
 Topical therapy with formulations containing 15% paromomycin,
and methlybenzethonium
 Physical treatment (heat, cryotherapy, laser, or a combination
of cryotherapy followed by intralesional pentavalent antimony)
 Systemic therapy (see ML)
 Infection by Viannia complex species
(especially L. [V.] braziliensis), multiple
or large (>4 cm) lesions, established
metastatic spread to lymph nodes, failure
to respond to topical treatment,
immune-suppressed patients
ML
 It must always be approached with
a systemic treatment
Gold standard:
 Meglumine antimoniate for intramuscular administration
(20 mg/kg/day without an upper limit for 20 [CL] to 28 [ML] days)
 Sodium stibogluconate for intravenous administration
(20 mg/kg/day without an upper limit for 20 [CL] to 28 [ML] days)
 plus oral pentoxyfilline 3  400 mg/day (CL)
Other approaches:
 Pentamidine isethionate (300 mg once weekly for 3e5 weeks)
 Miltefosine (150 mg/kg for 28 [CL] to 42 [ML] days)
 Fluconazole high dos es regimen (200e400 mg/day for at least 6 weeks)
 Azithromycin
 Amphotericin B (20 mg/kg in 5 days for CL; 40 mg/kg in 4e8 days for ML)
CL: cutaneous leishmaniasis; ML: mucosal leishmaniasis.
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cally chronic, ulcerative lesions are seen in 86e98% of cases
[45] (Table 3).4.2. Visceral leishmaniasis
Although very uncommon in travelers, VL should be sus-
pected in persons with an unexplained febrile illness,
especially when hepatosplenomegaly and thrombocyto-
penia are present, reporting a relevant travel history to an
endemic area. The long incubation period of leishmaniasis,
months or even years, makes it critically important for the
physicians to collect a sufficiently long personal history,
stressing possible travel to endemic areas. A search for risk
factors for HIV infection should also be considered,
including sexual encounters, intravenous drug use, and
blood transfusions obtained abroad [113]. The gold stan-
dard diagnostic tool for VL is, to date, microscopic exami-
nation of bone marrow smears characterized by >90%
sensitivity rates in children and 70% in adults. Higher
sensitivity rates (>95%) could be obtained from analysis of
spleen aspirates; however, in the context of profound
thrombocytopenia, spleen sampling may trigger life-threatening hemorrhage [19,128]. Serologic testing (indi-
rect hemagglutination assay, IHA, direct agglutination test,
DAT, enzyme-linked immunosorbent assay, ELISA, and in-
direct immunofluorescence, IFI) shows high sensitivity and
specificity rates, even though the diagnostic cut-offs
depend on the area and prevalence rates of asymptom-
atic infection. As a rule, antibody (IgG) detection tests
should complement other diagnostic tests, because they
remain detectable for several years after successful treat-
ment and do not usually distinguish between acute disease,
asymptomatic infections, relapses and cured cases [2]. The
complete anergy found during active disease state, limits
the availability of the Montenegro test for VL in the
detection of past infections [129]. The diagnosis can also be
confirmed with molecular methods (i.e. PCR), using various
clinical specimens (peripheral blood, bone marrow,
spleen), with high sensitivity and specificity rates
[128,130].
5. Treatment
Inappropriate management of leishmaniasis is common
[24,26,36]. Typically one patient with New World CL
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paid a total of 6600 US Dollars before the correct diagnosis
was considered [27]. To date an ideal anti-leishmanial
agent is far from being discovered; its desirable features
would be effectiveness, safety, ease of administration, and
affordability. The recent paper by Hodiamont et al. dem-
onstrates the lack of evidence in the literature for treat-
ment of several clinical categories with different
Leishmania species [131]. The choice of treatment is
influenced by previous experience as well as availability of
a particular drug within a country. Patients should be
referred to specialized centers with past experience.
5.1. Cutaneous and mucosal leishmaniasis
Factors that may influence the choice of therapeutic agent
include: (1) absence of evidence-based data regarding
travelers; (2) possible high toxicity associated with paren-
teral treatment for a usually benign self-healing disease
(with the exception of Viannia species induced New World
CL, where there is a risk of mucosal dissemination); (3) lack
of availability of appropriate drugs, especially pentavalent
antimonial agents, in certain countries, (4) compliance of
the patient [116]. Treatment is recommended to accelerate
cure and avoid or reduce disfiguring scars, as well as to
prevent mucosal dissemination. While a local treatment
might be sufficient for the first goal, a systemic one is
needed to achieve the second [116,132]. There are three
basic approaches to the treatment of Old World CL, ac-
cording to the specific features of lesions and patients. The
first involves single, stable lesions under 10 mm diameter
on non-exposed areas in an immunocompetent patient. In
such cases, intervention is not always necessary (“wait and
see”) as the ulcers should spontaneously regress within 2e4
months. In cases with more than one lesion in an exposed
area, topical treatment with intralesional injections is
generally initiated so as to expedite the healing process,
prevent disfiguring scarring, and reduce the likelihood of
dissemination and recurrence. In cases involving three or
more lesions larger than 4e5 cm, located in sensitive areas
(i.e. on the face or joints), systemic therapy becomes the
necessary approach. In brief, systemic treatment is indi-
cated in cases of 1) New World CL, in which skin lesions are
caused by Viannia complex species (especially L. [V.] bra-
ziliensis), 2) multiple or large (>4 cm) lesions, especially
when the face or a joint are affected or lesions are present
on the hands or feet, or for cosmetic reasons, 3) established
metastatic spread to lymph nodes, 4) failure to respond to
topical treatment, and 5) immune-suppressed patients.
Several studies show how early systemic treatment may
prevent mucosal lesions, which are seen more frequently in
patients with incomplete or missing specific treatment
[9,115,124,125,133,134] (Table 4).
5.1.1. Systemic pentavalent antimonials
The gold standard of CL and ML treatment is, to date,
represented by systemic pentavalent antimonials (meglu-
mine antimoniate for intramuscular administration, and
sodium stibogluconate for intravenous use), whose
biochemical basis of effectiveness is still unknown, but may
involve inhibition of ATP synthesis. These agents may bealso administered intralesionally [135]. However, the latter
method is not approved by the US Food and Drug Adminis-
tration (FDA). The recommended systemic dose is 20 mg/kg
once for day without an upper limit (no higher toxicity with
higher doses of the drug) for 20 days (CL suggested
regimen, to decrease the risk of mucosal invasion) to 28
days (ML suggested regimen, plus oral pentoxyfilline
3  400 mg/day) [136]. The pentavalent antimonials show
high cure rates and remain the mainstay of treatment for
CL or ML, providing cure with a low rate of recurrence
[116,132,137]. A recent meta-analysis concluded that
meglumine antimoniate is the drug of choice for ML with
88% cure rates compared to 51% cure rates for stibogluco-
nate [138e146]. However, pentavalent antimonials are far
from being ideal drugs because of their difficult adminis-
tration and toxicity. Fatigue, musculoskeletal pain, and
gastrointestinal symptoms (anorexia and nausea) are the
most common adverse effects. Occurrence of acute
pancreatitis during treatment among immune-suppressed
patients is noteworthy (e.g. patients co-infected with HIV
or those on immune-suppressive therapy following renal
transplant). Laboratory abnormalities are very common and
include higher levels of liver and pancreatic enzymes, and
hematological findings such as leucopenia and thrombocy-
topenia. Reversible ECG alterations (T wave changes) are
seen in 30e60% of cases and may occur without evidence of
myocardial damage. However, cardiac toxicity and poten-
tially lethal ventricular tachyarrhythmias, associated with
prolongation of the QT interval, have been documented and
increase with total drug accumulation. In addition, patients
with preexisting cardiovascular morbidity and hypo-
kalaemia are at particular risk and should be closely
monitored. It is therefore desirable that they be adminis-
tered by experienced personnel and only when medically
justified [139e146].
5.1.2. Pentamidine
A useful alternative to antimonials is pentamidine isethio-
nate, an aromatic diamidine, toxic for a number of pro-
tozoa and fungi, including Leishmania, Pneumocystis carinii
and African trypanosomes, whose mechanism of action has
not been established. Due to long experience in terms of
efficacy and safety it is considered the first-line agent for L.
[V.] guyanensis in French Guiana, Suriname, and Brazil. The
drug is less efficient against L. [L.] braziliensis infections
[147,148]. The drug is administered at a dose of 300 mg
once weekly for 3e5 weeks [132]. In an open-label study of
11 cases of imported Old World CL with large and chronic
lesions, a first line treatment consisting of three intra-
muscular injections of 4 mg/kg pentamidine base every
48 h yielded a success rate of 73% [149]. Elevation of
creatinine kinase has been noticed with much higher doses,
thus creatinine kinase and kidney function have to be
checked before each injection [132,150]. Glucose serum
levels should also be checked, since one case of hypergly-
cemia and glucosuria has been described after one 200 mg
dose of pentamidine [150].
5.1.3. Miltefosine
Miltefosine, a phosphocholine analog, is the first oral anti-
leishmanial drug. Preliminary studies show promising re-
sults with the use of the drug in New World CL and ML at a
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in ML, e.g., to 42 days). Oral miltefosine is effective against
L. major CL in Iran and L. [V.] braziliensis CL in Bolivia with
92.9% and 88% cure rates, respectively. Nevertheless the
same drug was found to be less effective in cases caused by
the same species in Guatemala, so a longer follow-up is
needed to evaluate the relapse rate [151]. However, mil-
tefosine has not proven useful to treat DCL [152].
The most notable side effects include nausea, vomiting,
diarrhea, motion sickness, and headache. An increase of
transaminases and creatinine kinase has also been reported
[132,151,153,154].
5.1.4. The imidazoles
The imidazoles and the structurally-related triazoles (flu-
conazole, itraconazole, and ketoconazole), originally used
as antifungal drugs, have also demonstrated anti-
leishmanial activity. They can be administered orally and
have a good safety profile [132]. However, they are only
effective against a limited number of Leishmania species. A
6-week course of oral fluconazole was shown to be safe and
effective over L. major CL in Iran, with cure rates of 36%
and 88% after 50 days and 90 days, respectively [155]. A
more recent randomized clinical trial in Iran showed that a
high dose fluconazole regimen (400 mg/day) had better
outcomes than the low-dose regimen (200 mg/day) [156].
Nevertheless, the effect of fluconazole has been ques-
tioned. In a recent study conducted among travelers with
imported L. major CL, a cure rate of 44.4% at day 50 was
recorded, comparable to published rates of spontaneous
healing [27].
5.1.5. Azithromycin
Azithromycin exhibits anti-leishmanial activity in vitro and
has also been used for the treatment of CL and ML. How-
ever, its use is limited to patients with treatment failure or
contraindications for all other options, such as young chil-
dren, pregnant women, or patients with a severe underly-
ing disease [157,158].
5.1.6. Amphotericin B
The first use of amphotericin B for the treatment of CL was
reported in the early 1960s when it was proved that the
main sterol in cellular membrane of Leishmania was
ergosterol [159]. Amphotericin B desoxycholate is active
against Leishmania species, but has the disadvantage of a
high incidence of adverse reactions (i.e. hyperpyrexia, se-
vere malaise, hypotension, thrombophlebitis, hepatitis,
hyperazotemia, renal tubular damage, hypokalemia, and
anemia). Several other amphotericin B lipid formulations
with much lower toxicity have been developed, proving
useful in the treatment of VL (see below). Based on
currently available data, liposomal amphotericin B has
been insufficiently studied, with regard to formulation and
dosage, to assess its efficacy in CL and ML. Despite this,
liposomal amphotericin B is being successfully used in
travelers as a first-line treatment in CL and ML, as a second-
line treatment after relapse, or in HIV-co-infected patients
(total dose of 20 mg/kg, in 5 days for CL; total dose of
40 mg/kg in 4e8 days for ML) [48,132].5.1.7. Local treatment
Local treatment is used exclusively when no risk for ML
seems plausible. It is mainly relevant in treating Leishmania
complex infections. Local treatment may be useful as an
adjuvant to systemic treatment to accelerate healing.
Local treatment may also be considered in patients for
whom systemic treatment is contraindicated, such as
pregnant women or subjects suffering from cardiac prob-
lems [132,160]. Drugs in topical formulations offer signifi-
cant advantages over systemic therapy, such as ease of
administration, fewer adverse effects and positive cost-
effectiveness ratio. However, the intact skin hampers
percutaneous absorption, mainly the stratum corneum.
Therefore, topical formulations may be applied to open
lesions that have lost their stratum corneum barrier prop-
erty, but are less successful in lesions where absorption is
hindered by epithelial thickening. Local infiltration of
pentavalent antimony maximizes the concentration within
lesions and has few systemic adverse effects; however, it
does not reach metastatic lesions. Intralesional infiltrations
are also painful and require some experience. The basic
aim of local treatment with pentavalent antimonials is to
fill the infected part of the dermis. The drug must not be
injected into the subcutaneous tissue, where it is rapidly
absorbed and does not reach the site of infection. However,
injection into the dermis is difficult, since the tissue space
is small. This means carefully infiltrating the area around
the lesion, including its base. A 25-fine gauge needle is used
to inject the drug under pressure as the needle advances.
Treatment should be given every 5e7 days, for a total of
two to five times. If the lesion is not healing after five
treatments, it should be re-examined in 1 month, when a
decision about switching to systemic treatment should be
made. When such injections are preceded by cryotherapy,
which involves bleaching of the lesion for 10 s, the result
is more efficacious than their individual use [161,162]. The
above-mentioned advantages of topical therapy are easily
obtained by formulations containing 15% paromomycin, an
aminoglycoside antibiotic, with methlybenzethonium in
white soft paraffin or urea and white soft paraffin, or with
0.5% gentamicin. The combination of paromomycin with
methylbenzethonium appears to be more effective than the
combination with urea, but it causes the strongest local
inflammatory reactions [132,163]. In L. [V.] braziliensis or
L. [V.] peruviana CL the efficacy of pentavalent antimonials
(also in terms of faster healing) seems to be improved by
the association of topical immune-modulators (e.g. imi-
quimod cream) [132]. The combination of oral pentoxyfil-
line 3  400 mg/day with antimonials for 28 days has proved
to have the same beneficial effects [160]. Physical treat-
ment for CL, such as heat, cryotherapy, laser, or a combi-
nation of cryotherapy with intralesional meglumine
antimoniate has been successfully applied in endemic
countries [164e167]. In particular, cryotherapy consists of
repeated topical applications of liquid nitrogen with a
cotton-tipped applicator or a cotton swab with moderate
pressure to the lesion, up to 2 mm outside the lesion
margin. The freezing time per application is 15e20 s. The
procedure must be repeated two or three times at short
intervals (1e2 days), resulting in a total time of 30e120 s.
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lesion reflects an adequate application. The usual post-
freeze pattern is some edema and blistering of the lesion
itself for 2e3 days, followed by crusting and formation of
an eschar [166,168].
5.2. Visceral leishmaniasis
Treatment for VL should be started as soon as the diagnosis
is established.
5.2.1. Systemic pentavalent antimonials
The pentavalent antimonials meglumine antimoniate and
sodium stibogluconate remain the standard anti-
leishmanial treatment for VL in developing endemic areas
with the exception of India, where their use has been
abandoned due to the occurrence of a widespread anti-
monial resistance, and they have been replaced with con-
ventional amphotericin B [132,169]. Experience with
antimonials for almost 70 years indicates efficacy rates of
>90e95% and low fatality and relapse rates
[107,135,170,171]. One advantage is their low cost; the
main disadvantages include intramuscular route of admin-
istration, prolonged (20 mg/kg once for day for 21e30 days)
schedules, and transient but occasionally life-threatening
side effects, such as increased serum hepatic trans-
aminases, pancreatitis, and cardiac arrhythmias [103].
5.2.2. Amphotericin B
Conventional amphotericin B has excellent anti-leishmanial
activity. A 15-day regimen at a dose of 0.75 mg/kg, seems
to result in cure rates over 90% in Indian VL [172]. Excluding
HIV-infected patients, relapses are rare. Even considering
its effectiveness, amphotericin B does not offer any
advantage over pentavalent antimonials for use outside
India, because of several disadvantages, including pro-
longed hospitalization and administration, and frequent
side effects (infusion-related fever and chills, nephrotoxi-
city, and hypokalemia) [135]. Lipid formulations of
amphotericin B (i.e. liposomal amphotericin B, amphoter-
icin B lipid complex, and amphotericin B colloidal disper-
sion) are selectively picked up by the reticulo-endothelial
system of the host, where parasites replicate, offering the
advantage of a highly localized and increased efficacy with
limited systemic toxicity. Contrary to what was said for the
conventional formulation, liposomal amphotericin B is the
first-line drug for VL in Europe, USA, and other industrial-
ized countries nowadays, offering great advantages
compared to pentavalent antimonials, because of its rapid
cure rates up to 100%, with a total dose of 20 mg/kg in 2e7
days, preferably 10 mg/kg once per day, on 2 consecutive
days, or a total dose of 40 mg/kg, administered over 4e8
days, for immunodeficient patients, improved compliance
of the patient, and reduced health care costs [173]. In HIV
co-infected patients, liposomal amphotericin B is also the
drug of choice both for treatment and for secondary pro-
phylaxis, because of its efficacy and safety profile [108],
while antimonials and conventional amphotericin B should
be avoided due to serious toxicity and intolerance [174].
However, in poorly resourced endemic countries even shortcourses of liposomal amphotericin B are unaffordable, but
nowadays the formulation is available at reduced price in
endemic countries, and for free for selected poor countries
[175]. In a recent study in India, injectable paromomycin
was shown not to be inferior to amphotericin B for the
treatment of VL [176].
5.2.3. Miltefosine
In a phase 4 trial of treatment with miltefosine in 1132 VL
adults and children in India, 95% cure rates were noted,
while adverse effects, including gastrointestinal toxicity
and increased hepatic transaminases and creatinine levels,
were noted in 3% of patients [177]. Currently, miltefosine is
licensed in India, Colombia, and Germany. It is adminis-
tered at a dose of 150 mg (in 2e3 doses) for 28 days in
adults >50 kg (50 mg/day in adults weighting <50 kg,
2.5 mg/kg/day in children), and 150 mg/day (in 2e3 doses)
for 6 weeks in immunodeficient patients [178]. Due to the
possible teratogenicity, miltefosine should not be adminis-
tered to women who may become pregnant within 2 months
after drug discontinuation.
6. Prevention
International travelers are frequently uninformed about
leishmaniasis and the appropriate protective measures. A
survey conducted among 373 travelers in Manu National
Park, Peru, revealed that only 6% of them had heard of
leishmaniasis, although 96.5% of the latter had received
pre-travel advice and 97.5% used protective measures
[179]. In another survey conducted among 58 American
travelers with New World CL, 53% reported that they have
heard about leishmaniasis, however only 29% were aware of
protective measures. Of note, 63% of the travelers who
reported not to have ever heard about leishmaniasis (47% of
the total) had received some pre-travel advice [30].
To date, no vaccine against human leishmaniasis is
available. Research and development of vaccines against
canine leishmaniasis have been stimulated by the economic
importance of dogs and their role as reservoirs of human
leishmaniasis caused by L. infantum in the Mediterranean
region and the Americas. Leishmune, containing the
fucose-mannose ligand antigen of L. donovani, is the first
licensed vaccine against canine leishmaniasis, with a re-
ported efficacy of 76e80% [180]. Travelers to endemic
areas should be advised that the only preventive measures
are to avoid sand fly bites, such as: 1) avoiding outdoor
activities, in particular from dusk to dawn when sand flies
are most active; 2) wear protective clothes (i.e. long-
sleeved shirts); 3) apply DEET (N,N-diethyl-meta-tolua-
mide)-containing repellents to exposed skin; 4) use of
permethrin-treated clothing, as shown in a study of
Colombian military personnel, in which soldiers wearing
permethrin-treated uniforms in an endemic area acquired
the disease significantly less often than those without
permethrin-treated clothing [180]. In addition, sand flies
are weak fliers and therefore their movement may be
inhibited by fans or ventilators. Sleeping in air-conditioned
or well-screened areas is also advisable, as well as indoor
spraying. Sand flies are smaller than mosquitoes and they
576 P. Mansueto et al.can pass through the holes of ordinary bed-nets (use only
fine-mesh bed netting). The treatment of bed-nets with a
pyrethroid-containing insecticide (permethrin or delta-
methrin) may protect against indoor transmission [181]. A
randomized study in Venezuela evaluated the imple-
mentation of pyrethroid-treated curtains in an urban area
with a 4% incidence of CL. A total of 2913 inhabitants from
569 homes were enrolled. The use of pyrethroid-treated
curtains reduced the sand fly population, and 12 months
later the incidence of CL was eliminated to 0% [181].
7. Conclusions
Among international travelers, imported leishmaniasis is an
uncommon but emerging infectious disease, whose man-
agement in developed, non-endemic countries is still a
challenge due to the unfamiliarity of physicians with its
wide clinical spectrum, diagnostic modalities, and available
treatment options. Leishmaniasis should be considered in
the diagnostic assessment of patients presenting with a
compatible clinical syndrome and a history of travel to an
endemic area, even if this occurred several months or years
before. Adventure travelers, researchers, military
personnel, and other groups of travelers likely to be
exposed to sand flies in endemic areas, should receive
counseling regarding leishmaniasis and appropriate pro-
tective measures.
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